Did You Know...
...that one person who claimed to be the inventor of the television is Russian emigre Vladimir Zworykin? In 1929 David Sarnoff, founder of RCA, asked Zworykin what it would take to develop TV for commercial use. He said: a year and a half and $100,000. In reality, it took 20 years and $50 million! Before his death in 1982 at the age of 92, Zworykin said of his invention: "The technique is wonderful. It is beyond my expectations. But the programs! I would never let my children even come close to this thing."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7939084 | Vaccine against varicella zoster virus Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE ant... | 05/10/2011 |
| 7811581 | Epstein Barr Virus (EBV) tumor-associated latent membrane extracellular domain peptides Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the outer cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents spec... | 10/12/2010 |
| 7763261 | Anti-human cytomegalovirus antibodies The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection. ... | 07/27/2010 |
| 7704510 | Cytomegalovirus surface protein complex for use in vaccines and as a drug target Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines com... | 04/27/2010 |
| 7501129 | Vectors comprising guinea pig CMV regulatory elements The invention comprises novel polynucleotides, and related vectors, host cells, methods, and compositions, containing transcriptional enhancers providing very high levels of expression of operably-linked expressible nucleic acid sequences in eukaryotic cells. Advant... | 03/10/2009 |
| 7427469 | Method of treating cytomegalovirus with DC-SIGN blockers The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN recept... | 09/23/2008 |
| 7422751 | Epstein-barr-virus-specific immunization The invention provides materials and methods for using EBV EBNA2 peptide epitopes to treat and/or prevent post-transplant lymphoproliferative disorders (PTLD). The invention also provides compositions and articles of manufacture containing EBNA2 peptide epitopes tha... | 09/09/2008 |
| 7419674 | Alpha virus-based cytomegalovirus vaccines The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fra... | 09/02/2008 |
| 7399825 | Synthetic peptide, inhibitor to DNA viruses The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which c... | 07/15/2008 |
| 7387782 | Protein kinase deficient, immunologically active CMVpp65 mutants This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the productio... | 06/17/2008 |
| 7326535 | Immunoreactive peptides from Epstein-Barr virus Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease. ... | 02/05/2008 |
| 7270990 | Virus production An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation ... | 09/18/2007 |
| 7271148 | Inhibition of cellular proteases The invention provides a method of decreasing viral replication in cells, the method comprising decreasing levels of functional cellular protease in the cells. The invention further provides a method of treating or preventing a viral infection in a subject, the meth... | 09/18/2007 |
| 7262045 | Methods of producing influenza vaccine compositions Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. ... | 08/28/2007 |
| 7208165 | Human cytomegalovirus DNA sequences Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for Preventing HCMV infections. ... | 04/24/2007 |
| 7204990 | Attenuation of cytomegalovirus virulence A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes. ... | 04/17/2007 |
| 7202331 | Therapeutic anti-cytomegalovirus compounds The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides met... | 04/10/2007 |
| 7192715 | Diagnostics and therapy of epstein-barr virus in autoimmune disorders Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducin... | 03/20/2007 |
| 7147861 | Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O bind... | 12/12/2006 |
| 7135186 | Varicella zoster virus (VZV) immunoreactive protein VP26 and its diagnostic use Varicella zoster virus (VZV) inimunoreactive protein VP26 and its diagnostic use are described. The invention relates to immunoreactive peptides which are homologous with the region of amino acid positions 12 to 235 (SEQ ID NO: 7) of the varicella zoster | 11/14/2006 |
| 7118755 | Herpes viruses for immune modulation An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus. ... | 10/10/2006 |
| 7112331 | Vaccines against varicella zoster virus gene 63 product The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella infections. The compositions of the invention comprise the protein enc... | 09/26/2006 |
| 7063851 | Herpes viruses for immune modulation A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which: (i) lacks a functional vhs gene, or... | 06/20/2006 |
| 7060283 | Immunoreactive peptides from Epstein-Barr virus Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino acids or less and has the formula (αETFTETWNRFITHTEβ) (SEQ ID NO:1), Γ... | 06/13/2006 |
| 7029678 | Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses. ... | 04/18/2006 |
| 7025968 | CMV vaccines The invention provides methods and compositions for inhibiting CMV infection and dissemination in an animal, as well as in vitro and in vivo assay systems for identifying such compositions. ... | 04/11/2006 |
| 7025969 | Protein kinase deficient, immunologically active CMVpp65 mutants This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the productio... | 04/11/2006 |
| 6951651 | CTL epitope analogs We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence. ... | 10/04/2005 |
| 6946448 | In utero oral nucleic acid immunization Methods of nucleic acid immunization comprising the in utero delivery of nucleic acid molecules that encode one or more selected antigens to a vertebrate fetus are disclosed. ... | 09/20/2005 |
| 6936251 | Peptide reagent for the detection of human cytomegalovirus (CMV) The invention relates to a peptide reagent comprising peptides immunochemically reactive with antibodies to the human cytomegalovirus (CMV). New antibodies directed to said peptides or fragments thereof are also part of the invention. Also cell lines capable of prod... | 08/30/2005 |
| 6899884 | Vaccine against mumps containing a jeryl-lynn virus strain A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and anitbody titres than know commercial vaccines. ... | 05/31/2005 |
| 6884422 | Freeze-dried hepatitis A attenuated live vaccine and its stabilizer The present invention relates to hepatitis A vaccine, especially to a lyophilized attenuated hepatitis A vaccine which can be stored at ambient temperature for extended periods of time, and to a method for producing the same. The present invention further relates to... | 04/26/2005 |
| 6843992 | Immuno-reactive peptide CTL epitopes of human cytomegalovirus The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) inf... | 01/18/2005 |
| 6843997 | Variant varicella-zoster viruses and methods of use The present invention provides methods directed to detecting antibodies that specifically bind to a varicella zoster polypeptide, detecting the presence of a varicella zoster virus in an animal, diagnosing a disease caused by varicella zoster virus, and detecting a ... | 01/18/2005 |
| 6835383 | Protein kinase deficient, immunologically active CMVpp65 mutants This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the productio... | 12/28/2004 |
| 6740324 | Methods and compositions useful for stimulating an immune response The invention provides compositions containing modified cytomegalovirus, and methods of using the compositions. In various embodiments, the modifications include adding a heterologous sequence encoding a non-viral chemokine element and/or immunogenic polypeptide, an... | 05/25/2004 |
| 6733973 | Diagnostic reagents for human cytomegalovirus and methods of use The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) inf... | 05/11/2004 |
| 6726910 | Immuno-reactive peptide CTL epitopes of human cytomegalovirus The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) inf... | 04/27/2004 |
| 6723558 | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using ... | 04/20/2004 |
| 6713070 | Viral particles which are released after the infection with the human cytomegalovirus, and the use of said particles as a vaccine The invention relates to viral particles which are released by mammal cells after the infection with human cytomegalovirus (HCMV). The invention also relates to particles whose antigenicity has been optimized by changing the HCMV using genetic engineering. The inven... | 03/30/2004 |
